| |
21st Nationwide survey n; %
|
Second cohort group n; %
|
p-value
|
Odds ratio
|
95% CI
|
|---|
|
Total
|
23,730; 100.0
|
112; 100.0
| |
(crude)
| |
|
Initial IVIG therapy
|
21,247; 89.5
|
104; 92.9
|
0.24
|
0.46
|
0.23–0.95
|
| | | |
0.31*
|
1.20*
|
0.86–1.69*
|
|
Acute phase CAL
|
2,044; 8.6
|
3; 2.7
|
0.03
|
3.43
|
1.09–10.79
|
|
Cardiac sequelae
|
696; 2.9
|
1; 0.9
|
0.32
|
3.35
|
0.47–24.06
|
|
Additional IVIG therapy
|
4,049; 17.1
|
10; 8.9
|
0.02
|
2.10
|
1.10–4.02
|
|
Resistance for IVIG therapy
|
3,532; 14.9
|
4; 3.6
|
< 0.001
|
5.16
|
1.09–14.00
|
- *Adjusted odds ratio for dosage of initial IVIG therapy in both groups was obtained using the Mantel-Haenstzel method adjusted for various initial dosages of intravenous immunoglobulin (2 g/kg, 1 g/kg, 400 mg/kg, or various dosages of IVIG). Adjusted odds ratio for acute-phase CAL, cardiac sequelae, and additional IVIG therapy were not analyzed because there were no descriptions of dosages of various initial IVIG in the nationwide surveys.
